Mendus AB (publ) (STO:IMMU)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.975
+0.110 (2.26%)
Apr 25, 2025, 5:29 PM CET
-49.23%
Market Cap 250.54M
Revenue (ttm) n/a
Net Income (ttm) -128.40M
Shares Out 50.36M
EPS (ttm) -2.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,112
Average Volume 29,524
Open 5.390
Previous Close 4.865
Day's Range 4.900 - 5.440
52-Week Range 4.455 - 11.200
Beta 0.76
RSI 31.73
Earnings Date Apr 15, 2025

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 28
Stock Exchange Nasdaq Stockholm
Ticker Symbol IMMU
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.